Proteomics International (ASX:PIQ) Appoints New CEO as US Sales Push Begins: Is It Time to Buy?

Proteomics International begins its US sales push as Medicare reimbursement starts

At Proteomics International (ASX: PIQ), new CEO David Morris takes the reins today as the Perth-based medical technology company shifts from research and development to commercial execution. This leadership change comes at a critical time, as US Medicare reimbursement of US$390.75 per test went live on January 1, 2026, opening the door to the world’s largest healthcare market.

For investors, the timing is interesting. The company has spent years developing its PromarkerD test, which can predict diabetic kidney disease up to four years before symptoms appear. Now, with the regulatory and reimbursement pieces falling into place, the question is whether new leadership can turn this potential into real revenue.

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

New Leadership Signals Commercial Pivot

David Morris brings more than 25 years of experience commercialising medical devices at Australia’s most successful healthcare companies. He spent over 14 years at Cochlear, the global leader in hearing implants, where he rose to Chief Strategy Officer. He later served at Nanosonics and as CEO of Monash IVF Group.

This background matters because Proteomics International is moving from development to commercial execution. Morris has done exactly this before, helping scale medical technology businesses across international markets. Founder Dr Richard Lipscombe announced his retirement in September 2025 and is scheduled to formally step down on February 23, 2026, following a transition period.

PromarkerD and the US Market Opportunity

The company’s flagship product, PromarkerD, is a simple blood test that predicts diabetic kidney disease before symptoms appear. This matters because early detection allows doctors to prescribe treatments that can slow or stop kidney damage. Currently, most tests only detect the disease after irreversible damage has occurred.

The US market opportunity is substantial. Around 32 million Americans live with diabetes, and diabetic kidney disease costs the US healthcare system US$130 billion per year. Medicare and Medicaid cover about 42% of all US healthcare spending, so the new reimbursement price creates a clear pathway for doctors to order the test and get paid.

The company has also secured recent patent wins. It bolstered its IP portfolio last week with the grant of a Canadian patent for PromarkerEso, following its earlier US patent win. PromarkerEso is a diagnostic blood test for oesophageal cancer. The company’s US laboratory also recently received accreditation from the College of American Pathologists. These milestones strengthen intellectual property protection and expand commercial capabilities.

The Investor’s Takeaway for Proteomics International

At around A$0.80 per share, Proteomics International has a market cap of approximately A$131 million. Some analyst valuations suggest significant upside, with price targets ranging up to A$2.34. However, investors should approach these targets with caution, as they depend on assumptions about future sales that remain unproven.

The bull case is compelling. US Medicare reimbursement creates a clear payment pathway covering over 67 million Americans. Recent patent wins strengthen the company’s competitive position. The new CEO has a proven track record of commercialising medical devices.

The bear case is equally real. Proteomics International remains pre-revenue on its diagnostic products, meaning execution risk is high. Converting Medicare reimbursement into actual test sales requires building distribution channels and physician awareness, which takes time and money.

Our view: This is a speculative opportunity for risk-tolerant investors who believe the new CEO can deliver commercial results. The next 12 months will be critical. Watch for early signs of US test volumes and any announcements about new distribution partnerships.